MARKET

SNY

SNY

Sanofi FR
NASDAQ
46.72
-0.03
-0.06%
After Hours: 46.75 +0.03 +0.06% 16:36 12/01 EST
OPEN
46.50
PREV CLOSE
46.75
HIGH
46.86
LOW
46.28
VOLUME
1.16M
TURNOVER
0
52 WEEK HIGH
57.82
52 WEEK LOW
42.63
MARKET CAP
117.16B
P/E (TTM)
24.47
1D
5D
1M
3M
1Y
5Y
Sanofi FR: Report of foreign issuer
Press release · 6h ago
EU regulators seeking more info on GLP-1s and suicidal thoughts: report
European regulators are looking into whether certain diabetes and weight-loss drugs may trigger suicidal thoughts in some users. The european medicines agency began a review in july after receiving at least 170 reports. Novo nordisk and eli lilly are among drugmakers under investigation for possible link.
Seeking Alpha · 7h ago
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Ema will request further clarifications from drugmakers of glp-1 receptor agonists for diabetes and weight loss. Novo nordisk's popular therapies ozempic and wegovy have been linked to suicidal thoughts. Ema received reports of two cases of suicidal thoughts linked to the drugs in july.
Benzinga · 8h ago
Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More
NASDAQ · 13h ago
How Is The Market Feeling About Sanofi?
Sanofi's short percent of float has fallen 25.0% since its last report. The company has 3.73 million shares sold short, which is 0.15% of all regular shares. Short interest is the number of shares that have been sold short but not yet covered.
Benzinga · 1d ago
Teva Completes Closing Of Exclusive Collaboration Deal To Deliver Inflammatory Bowel Disease Treatment
Teva and sanofi close collaboration deal to co-develop and co-commercialize asset tev '574. Teva will receive upfront payment of $500 million and up to $1 billion in development milestones. Tev '574 is in phase 2b clinical trials for the treatment of ulcerative colitis and crohn's disease.
Benzinga · 1d ago
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Two biotech stocks can provide solid returns through the next decade. Sanofi and gilead sciences are two companies that can continue to innovate and develop new medicines. Sanilly's recent sell-off is overdone; the company's new products should be a growth driver in the future. Gilead sciences is a leader in the hiv market.
The Motley Fool · 1d ago
Manufacturers, Senior Administration Officials Agreed To Plan Now To Meet Next Year's Projected Demand For RSV Vaccines
Benzinga · 3d ago
More
About SNY
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Webull offers Sanofi SA (ADR) stock information, including NASDAQ: SNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNY stock methods without spending real money on the virtual paper trading platform.